2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Tuesday, November 7, 2017

9:00AM-11:00AM: Abstract Number: 2429

Towards Precision Medicine in Rheumatoid Arthritis (RA): Trans-Ethnic Analysis and Prioritization of SNPs in the AFF3 Locus

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2516

Trabecular Bone Score As an Assessment Tool to Identify the Risk of Osteoporosis in Axial Spondyloarthritis: A Case-Control Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2095

Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2205

Trajectories of Knee Bone Shape Change Are Associated with Sex and Osteoarthritis

Osteoarthritis – Clinical Aspects Poster II: Observational and Epidemiological Studies

9:00AM-11:00AM: Abstract Number: 2433

Transcriptome Analysis in Women with Rheumatoid Arthritis Who Improve or Worsen during Pregnancy

Rheumatoid Arthritis – Human Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2342

Transcriptomic Analysis Reveals Mitochondrial and Monocyte Dysfunctions Are Linked to the Interferonopathy of Juvenile Dermatomyositis

Pediatric Rheumatology – Pathogenesis and Genetics Poster

9:00AM-11:00AM: Abstract Number: 2285

Treatment of Adult Juvenile Idiopathic Arthritis Patients with Biologic Agents. Data from the National Registry

Pediatric Rheumatology – Clinical and Therapeutic Aspects Poster III: Juvenile Arthritis

9:00AM-11:00AM: Abstract Number: 2067

Treatment with Pegloticase Significantly Decreases Mean Arterial Blood Pressure in Patients with Chronic Gout

Metabolic and Crystal Arthropathies Poster II

9:00AM-11:00AM: Abstract Number: 2654

Treatment-Associated DNA Methylation Patterns in Systemic Lupus Erythematosus

Systemic Lupus Erythematosus – Human Etiology and Pathogenesis Poster II

9:00AM-11:00AM: Abstract Number: 1952

Trend of Arthrocentesis Utilization Among Inpatients over 10 Years – Data from National Inpatient Sample

Epidemiology and Public Health Poster III: Rheumatic Disease Risk and Outcomes

9:00AM-11:00AM: Abstract Number: 2390

Trends and Predictors of Guideline Adherence for Glucocorticoid-Induced Osteoporosis Prevention in an Early Rheumatoid Arthritis Cohort

Rheumatoid Arthritis – Clinical Aspects Poster III: Comorbidities

9:00AM-11:00AM: Abstract Number: 2505

Trends in Time to Diagnosis in Spondyloarthritis Patients. Association with 2009 ASAS Classification Criteria and Clinical Presentation at Disease Onset. Data from Comospa Study

Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

9:00AM-11:00AM: Abstract Number: 2670

Trigeminal Neuralgia in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2689

Troponinemia Independently Associates with Mortality in Systemic Sclerosis

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster III

9:00AM-11:00AM: Abstract Number: 2127

Tumor Necrosis Factor Inhibitors for Sarcoidosis

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].